欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2021, Vol. 26 ›› Issue (7): 744-752.doi: 10.12092/j.issn.1009-2501.2021.07.004

• 基础研究 • 上一篇    下一篇

二甲双胍对TGF-β1诱导的大鼠肺泡上皮II型细胞间质转分化的影响

郝伟1,左东泽2,张俊秀2,蒋莉莉2,熊莺2,杨解人2   

  1. 1皖南医学院机能学实验实训中心,芜湖 241000,安徽;2皖南医学院药理学教研室,芜湖 241000,安徽
  • 收稿日期:2020-11-02 修回日期:2021-06-15 出版日期:2021-07-26 发布日期:2021-08-09
  • 通讯作者: 杨解人,女,本科,教授,研究方向:心血管药理学。 Tel: 13955382763 E-mail: jryang1955@sina.com
  • 作者简介:郝伟,女,研究生,实验师,研究方向:临床药理学。 Tel: 17856938796 E-mail: 447385573@qq.com
  • 基金资助:
    安徽省高校优秀青年人才支持计划重点项目资助(gxyqZD2016170);2016年皖南医学院校中青年科研基金资助(WK201602)

Effects of metformin on epithelial-mesenchymal transition of rat alveolar epithelial type II cells induced by TGF-β1

HAO Wei 1, ZUO Dongze 2, ZHANG Junxiu 2, JIANG Lili 2, XIONG Ying 2, YANG Jieren 2   

  1. 1 Kinesiology Experimental Training Center, Wannan Medical College, Wuhu 241000, Anhui, China
  • Received:2020-11-02 Revised:2021-06-15 Online:2021-07-26 Published:2021-08-09

摘要: 目的:观察二甲双胍(metformin, Met)对大鼠肺泡上皮II型细胞(rat alveolar epithelial type II cells, RLE-6TN)间质转分化(endothelial-mesenchymal transition, EMT)的影响及其可能的机制。方法:实验分为6组:Control组;转化生长因子-β1(transforming growth factor-β1, TGF-β1)组:细胞用TGF-β1(5 ng/mL)处理48 h;TGF-β1+Met(1、10、100 μmol/L)组:细胞先用Met(1、10、100 μmol/L)预处理1 h,再用TGF-β1(5 ng/mL)处理48 h;Met(100 μmol/L)组:细胞用Met(100 μmol/L)处理48 h。CCK-8法检测细胞增殖。RT-PCR检测细胞α-平滑肌肌动蛋白(α-smooth muscle actin, α-SMA)、波形蛋白(vimentin)、E钙粘附蛋白(E-Cadherin)、紧密连接蛋白-1(zonulaoccludens, ZO-1)、I型胶原(collagen I)、III型胶原(collagen III)的mRNA表达。Western blotting检测α-SMA、vimentin、E-Cadherin、ZO-1、collagen I、collagen III的蛋白表达及Smad2/3和细胞外调节蛋白激酶1/2(extracellular regulated protein kinases 1/2, ERK1/2)的蛋白磷酸化水平。结果: 与TGF-β1组比,二甲双胍(10、100 μmol/L)可显著抑制TGF-β1诱导的RLE-6TN细胞增殖(P<0.05或P<0.01),降低α-SMA、vimentin、collagen I、collagen III的mRNA和蛋白表达及Smad2/3和ERK1/2的蛋白磷酸化水平(P<0.05或P<0.01),增加E-cadherin和ZO-1的mRNA和蛋白表达(P<0.05或P<0.01)。结论:二甲双胍(10、100 μmol/L)对TGF-β1诱导的RLE-6TN细胞EMT具有一定的抑制作用,其机制可能与抑制Smad2/3和ERK1/2的磷酸化有关。

关键词: 二甲双胍, 肺纤维化, 内皮-间质转化, 转化生长因子-β1

Abstract: AIM: To observe the effect of metformin (Met) on the endothelial-mesenchymal transition (EMT) of rat alveolar epithelial type II cells and its mechanism. METHODS: The RLE-6TN cells were divided into 6 groups as follows: Control group; transforming growth factor-β1 (TGF-β1) group in which cells were incubated with TGF-β1 (5 ng/mL) for 48 h; TGF-β1+Met (1, 10, 100 μmol/L) group in which cells were pre-treated with Met (1, 10, 100 μmol/L) for 1 h, and then subjected to TGF-β1 (5 ng/mL) for 48 h; Met (100 μmol/L) group in which cells were incubated with Met (100 μmol/L) for 48 h. CCK-8 method was used to detect the cell proliferation. RT-PCR detected α-smooth muscle actin (α-SMA), vimentin, E-Cadherin, tight junction protein-1 (ZO-1), collagen I and collagen III mRNA expression. Western blotting was used to detect the protein expression of α-SMA, vimentin, E-Cadherin, ZO-1, collagen I, collagen III and levels of phosphorylated Smad2/3 and extracellular regulated protein kinases (ERK1/2). RESULTS: Metformin significantly inhibited the proliferation of RLE-6TN cells induced by TGF-β1 (P<0.05 or P<0.01), reduced the mRNA and protein expression of α-SMA, vimentin, collagen I, collagen III, and decreased the protein phosphorylation of Smad2/3 and ERK1/2 Level (P<0.05 or P<0.01) when compared with the TGF-β1 group. Conversely, metformin treatment increased the mRNA and protein expression of E-cadherin and ZO-1 (P<0.05 or P<0.01) compared with the TGF-β1 group. CONCLUSION: Metformin (10, 100 μmol/L) exhibits certain inhibitory effect on the EMT of RLE-6TN cells induced by TGF-β1, and its beneficial effects may be associated with the inhibition of the phosphorylation of Smad2/3 and ERK1/2.

Key words: metformin, pulmonary fibrosis, endothelial-mesenchymal transition, TGF-β1

中图分类号: